AstraZeneca's basic earnings per share (Basic EPS) for the
three
months ended in Mar. 2026 was ARS2,782.51.
Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was ARS9,062.71.
AstraZeneca's EPS (Diluted) for the
three
months ended in Mar. 2026 was ARS2,754.54.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ARS8,981.20.
AstraZeneca's EPS without NRI for the
three
months ended in Mar. 2026 was ARS2,754.54.
Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 8,981.20.
During the past 12 months, AstraZeneca's average EPS without NRIGrowth Rate was 27.90% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 32.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 13 years, AstraZeneca's highest 3-Year average EPS without NRI Growth Rate was 338.40% per year. The lowest was -73.20% per year. And the median was 9.80% per year.
AstraZeneca (BUE:AZN) EPS (Basic) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
AstraZeneca EPS (Basic) Related Terms
AstraZeneca EPS (Basic) Historical Data
* Premium members only.
The historical data trend for AstraZeneca's EPS (Basic) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
AstraZeneca's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as
EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS9,062.71
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AstraZeneca (BUE:AZN) has a EPS (Basic) of ARS9,062.71 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on AstraZeneca and its competitors.
Is AstraZeneca's EPS (Basic) too high?
AstraZeneca's current EPS (Basic) is ARS9,062.71. Overall, AstraZeneca has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca's EPS (Basic) compare to LLY and JNJ?
AstraZeneca's EPS (Basic) of ARS9,062.71 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on AstraZeneca and its competitors. AstraZeneca's current EPS (Basic) is ARS9,062.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca (BUE:AZN) is currently considered Fairly Valued. The stock's GF Value™ is ARS69,153.76, compared to a current price of ARS70,900.00 — trading 2.5% above its estimated fair value. The current EPS (Basic) is ARS9,062.71. AstraZeneca's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For AstraZeneca (BUE:AZN), the current EPS (Basic) is ARS9,062.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AstraZeneca (BUE:AZN) Overvalued in 2026?
Based on GuruFocus' analysis, AstraZeneca stock appears to be overvalued.
The current stock price of ARS70,900.00 is trading 2.5% above its estimated GF Value™ of ARS69,153.76.
GuruFocus considers AstraZeneca to be Fairly Valued.
Key valuation signals for BUE:AZN:
EPS (Basic): ARS9,062.71
GF Value™: ARS69,153.76 vs. price of ARS70,900.00 (2.5% above fair value)
No single metric tells the full story. See the BUE:AZN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
77GF Score
Get the complete analysis for BUE:AZN
EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUE:AZN has been successfully added to your 
